KR20200042311A - Compositions for for inhibiting of macrophage death by triglycerides comprising extracts of Angelica takeshimana - Google Patents
Compositions for for inhibiting of macrophage death by triglycerides comprising extracts of Angelica takeshimana Download PDFInfo
- Publication number
- KR20200042311A KR20200042311A KR1020180122744A KR20180122744A KR20200042311A KR 20200042311 A KR20200042311 A KR 20200042311A KR 1020180122744 A KR1020180122744 A KR 1020180122744A KR 20180122744 A KR20180122744 A KR 20180122744A KR 20200042311 A KR20200042311 A KR 20200042311A
- Authority
- KR
- South Korea
- Prior art keywords
- triglycerides
- extract
- composition
- present
- death
- Prior art date
Links
- 210000002540 macrophage Anatomy 0.000 title claims abstract description 56
- 150000003626 triacylglycerols Chemical class 0.000 title claims abstract description 44
- 239000000284 extract Substances 0.000 title claims abstract description 41
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- 230000034994 death Effects 0.000 title claims abstract description 31
- 230000002401 inhibitory effect Effects 0.000 title claims description 23
- 244000061520 Angelica archangelica Species 0.000 title 1
- 235000001287 Guettarda speciosa Nutrition 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 20
- 230000036541 health Effects 0.000 claims abstract description 17
- 235000013376 functional food Nutrition 0.000 claims abstract description 14
- 244000025254 Cannabis sativa Species 0.000 claims description 9
- 230000002147 killing effect Effects 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 7
- 244000302909 Piper aduncum Species 0.000 claims description 2
- 235000016761 Piper aduncum Nutrition 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 abstract description 5
- 239000008280 blood Substances 0.000 abstract description 5
- 244000131415 Zanthoxylum piperitum Species 0.000 abstract 3
- 235000008853 Zanthoxylum piperitum Nutrition 0.000 abstract 3
- 230000000694 effects Effects 0.000 description 14
- 210000000497 foam cell Anatomy 0.000 description 10
- 239000003814 drug Substances 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 201000001320 Atherosclerosis Diseases 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 8
- 206010003210 Arteriosclerosis Diseases 0.000 description 7
- 208000011775 arteriosclerosis disease Diseases 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000005194 fractionation Methods 0.000 description 5
- 229940116257 pepper extract Drugs 0.000 description 5
- 239000011651 chromium Substances 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- -1 etc.) Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000005445 natural material Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 235000013923 monosodium glutamate Nutrition 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 208000004371 toothache Diseases 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- GGLIEWRLXDLBBF-UHFFFAOYSA-N Dulcin Chemical compound CCOC1=CC=C(NC(N)=O)C=C1 GGLIEWRLXDLBBF-UHFFFAOYSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 244000187664 Nerium oleander Species 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- 239000004288 Sodium dehydroacetate Substances 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 241000949456 Zanthoxylum Species 0.000 description 1
- 241001079064 Zanthoxylum schinifolium Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- PARMADWNFXEEFC-UHFFFAOYSA-N bamethan sulfate Chemical compound [O-]S([O-])(=O)=O.CCCC[NH2+]CC(O)C1=CC=C(O)C=C1.CCCC[NH2+]CC(O)C1=CC=C(O)C=C1 PARMADWNFXEEFC-UHFFFAOYSA-N 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000001164 bioregulatory effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000008126 dulcin Substances 0.000 description 1
- NWNUTSZTAUGIGA-UHFFFAOYSA-N dulcin Natural products C12CC(C)(C)CCC2(C(=O)OC2C(C(O)C(O)C(COC3C(C(O)C(O)CO3)O)O2)O)C(O)CC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1OC1OC(CO)C(O)C(O)C1O NWNUTSZTAUGIGA-UHFFFAOYSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000001120 potassium sulphate Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 1
- 229940079839 sodium dehydroacetate Drugs 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/758—Zanthoxylum, e.g. pricklyash
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Diabetes (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 산초 추출물을 포함하는 중성지방에 의한 대식세포 사멸 억제용 조성물에 관한 것으로, 산초 추출물 또는 이의 분획물을 유효성분으로 포함하는 중성지방에 의한 대식세포 사멸 억제용 조성물, 건강기능식품 조성물 및 중성지방에 의한 대식세포 사멸 억제 방법에 관한 것이다.
The present invention relates to a composition for inhibiting macrophage death by triglycerides, including a mountain extract, a composition for inhibiting macrophage death by triglycerides, which contains a mountain extract or a fraction thereof as an active ingredient, a health functional food composition, and neutrality It relates to a method for inhibiting the death of macrophages by fat.
중성지방은 지단백의 가운데 부분을 구성하는 지질이며, 이차적인 원인에 의한 농도의 상승이 흔하게 나타난다. 예로서, 비만, 운동부족, 흡연, 과량의 음주, 탄수화물의 다량섭취 등과 당뇨병, 만성신부전, 신증후군 등의 질환 및 베타차단제, 스테로이드, 에스트로겐 등의 약제에 의해서 혈중 중성지방 농도가 상승할 수 있다.
Triglycerides are lipids that make up the middle part of lipoproteins, and an increase in concentration due to secondary causes is common. For example, obesity, lack of exercise, smoking, excessive drinking, high intake of carbohydrates, diabetes, chronic kidney failure, nephrotic syndrome and other diseases and beta-blockers, steroids, estrogen, etc. .
상술한 중성지방은 동맥경화증의 발병에도 관여하는데, 동맥경화증의 구체적인 발병 기전은 다음과 같다. 먼저, 단핵세포(monocyte)가 대식세포(macrophage)로 분화하고, 분화한 대식세포는 HDL/LDL-콜레스테롤 또는 중성지방을 탐식하여 사멸하거나 거품세포(foam cell)가 된다. 생성된 거품세포는 지속적으로 염증반응을 유도하는데, 시간이 지남에 따라 거품세포는 세포자연사(apoptosis)를 통해 사멸되고 사멸된 세포는 새로 이동해온 대식세포에 의해 제거된다. 그러나, 사멸된 거품세포 중 일부는 제거되지 않고 남아 주위의 세포에 이차적으로 괴사(necrosis)를 유발하고, 이로 인해 죽상판(plaque) 내 염증반응이 증가하고 결과적으로 동맥경화증이 악화된다(Golias C, In Vivo., 2007, 21(5):757-69.; Thorp E, J Leukoc Biol., 2009, 86(5):1089-95.; Tabas I. Antioxid Redox Signal., 2009, 11(9):2333-9.).
The aforementioned triglycerides are also involved in the development of atherosclerosis, and the specific mechanism of development of atherosclerosis is as follows. First, monocytes differentiate into macrophage, and the differentiated macrophages kill HDF / LDL-cholesterol or triglycerides or die or become foam cells. The resulting foam cells continuously induce an inflammatory response. Over time, the foam cells are killed through apoptosis, and the dead cells are removed by newly migrated macrophages. However, some of the killed foam cells remain unremoved, causing secondary necrosis to surrounding cells, which increases the inflammatory response in the plaque and worsens atherosclerosis (Golias C). , In Vivo., 2007, 21 (5): 757-69 .; Thorp E, J Leukoc Biol., 2009, 86 (5): 1089-95 .; Tabas I. Antioxid Redox Signal., 2009, 11 (9 ): 2333-9.).
또한, 비만, 고지혈증 등에 의하여 혈중 중성지방 농도가 높아지는 경우 대식세포가 거품세포로 전환되거나, 중성지방에 의해 사멸되는 비율이 높아진다. 즉, 대식세포가 사멸됨에 따라 이의 면역기능 및 중성지방 대사기능이 저하되고, 형성된 거품세포의 제거기능이 저하되어 결국 동맥경화증이 발병하거나 악화될 가능성이 높아진다. 따라서, 동맥경화증의 발병 또는 악화를 예방하기 위해서는 혈중 중성지방 농도가 높은 상태에서도 대식세포가 거품세포를 제거하는 제기능을 유지하게 하거나, 중성지방에 의해 사멸되는 것을 최소화하는 것이 중요하다.
In addition, when the concentration of triglycerides in the blood increases due to obesity, hyperlipidemia, etc., the rate at which macrophages are converted into foam cells or killed by triglycerides increases. That is, as the macrophages die, their immune function and triglyceride metabolism decreases, and the removal function of the formed foam cells decreases, which increases the likelihood of developing or worsening atherosclerosis. Therefore, in order to prevent the development or exacerbation of arteriosclerosis, it is important to keep macrophages functioning to remove foam cells even when the concentration of triglycerides in the blood is high, or to minimize the death by triglycerides.
현재, 이러한 동맥경화증의 치료에는 로수바스타틴, 심바스타틴 등의 스타틴계 약물이 주로 사용되고 있으나, 이는 거품세포를 제거하는 대식세포의 활성을 감소시키는 부작용이 있는 것으로 알려져 있다. 이외에도, 스타틴계 약물은 당뇨병, 근육 이상증, 과혈당증 등의 부작용을 야기하는 것이 문제점으로 지적된바, 부작용이 보다 적은 천연물에 대한 연구가 필요한 실정이다.
Currently, statin-based drugs such as rosuvastatin and simvastatin are mainly used for the treatment of atherosclerosis, but it is known that there is a side effect of reducing the activity of macrophages to remove foam cells. In addition, the statin-based drug is pointed out as a problem that causes side effects such as diabetes, muscular dystrophy, and hyperglycemia, and studies on natural products with fewer side effects are needed.
이에 따라, 아까시나무 추출물을 함유하는 동맥경화증 치료용 조성물(한국 공개특허공보 제10-2016-0084990호), 장뇌삼 발효 추출물을 포함하는 항고지혈증 및 항동맥경화 조성물(한국 공개특허공보 제10-2016-001805호), 환삼덩굴 추출물을 포함하는 동맥경화의 예방 또는 치료용 조성물(한국 등록특허공보 제10-1516764호) 등 천연 물질을 이용한 동맥경화증의 예방 또는 치료제가 개발된 바 있다.
Accordingly, the composition for the treatment of atherosclerosis containing the extract of oleander (Korea Patent Publication No. 10-2016-0084990), anti-hyperlipidemia and anti-arteriosclerosis composition containing the camphor ginseng fermentation extract (Korea Patent Publication No. 10-2016 -001805), prevention or treatment of arteriosclerosis using natural substances, such as a composition for the prevention or treatment of arteriosclerosis containing the extract of ginseng vine (Korea Patent Publication No. 10-1516764) has been developed.
한편, 산초(Zanthoxylum schinifolium)는 높이 3m, 수관폭 2m로 우산모양을 이루는 수목이다. 꽃은 주로 9월에 피는데 연한 녹색이고 향기가 없으며, 열매는 녹갈색이고 흑색 종자가 들어 있다. 한의학에서는 산초의 과피(pericarp, 과실에서 종자를 제외한 부분)를 소화불량, 구토, 치통, 이질, 설사, 회충구제 등을 위한 치료제로 사용한다고 한다. 그러나, 중성지방에 의한 대식세포의 사멸 억제 효과 또는 이에 따른 동맥경화증 치료 효과는 공지된 바 없었다.
Meanwhile, Zanthoxylum schinifolium ) is a tree that forms an umbrella with a height of 3m and a water pipe width of 2m. Flowers bloom mainly in September, light green, scentless, fruit greenish brown with black seeds. It is said that oriental medicine uses pericarp (pericarp, except for seeds from fruits) as a treatment for indigestion, vomiting, toothache, dysentery, diarrhea, and roundworms. However, the effect of inhibiting the death of macrophages by triglycerides or the effect of treating arteriosclerosis accordingly has not been known.
이러한 배경하에, 본 발명자들은 동맥경화증에 대하여 예방 또는 치료 효과를 나타낼 수 있는, 중성지방에 의한 대식세포 사멸 억제 효과를 갖는 천연 물질을 개발하고자 예의 노력 연구한 결과, 산초 추출물이 중성지방에 의한 대식세포의 사멸을 억제하는 효과를 나타냄을 확인하여, 본 발명을 완성하였다.
Under these backgrounds, the present inventors have studied in earnest efforts to develop a natural substance having an inhibitory effect on macrophage death by triglycerides, which can have a prophylactic or therapeutic effect on arteriosclerosis, and as a result, the extract of wild pepper is caused by triglycerides. The present invention was completed by confirming the effect of suppressing the death of phagocytes.
본 발명의 하나의 목적은 산초 추출물 또는 이의 분획물을 유효성분으로 포함하는, 중성지방에 의한 대식세포 사멸 억제용 조성물을 제공하는 것이다.One object of the present invention is to provide a composition for inhibiting macrophage killing by triglycerides, comprising an extract of wild grass or a fraction thereof as an active ingredient.
본 발명의 다른 하나의 목적은 상기 조성물을 개체에 투여하는 단계를 포함하는, 중성지방에 의한 대식세포 사멸 억제 방법을 제공하는 것이다.Another object of the present invention is to provide a method for inhibiting macrophage death by triglycerides, comprising administering the composition to an individual.
본 발명의 또 다른 하나의 목적은 산초 추출물 또는 이의 분획물을 유효성분으로 포함하는, 중성지방에 의한 대식세포 사멸 억제용 건강기능식품 조성물을 제공하는 것이다.
Another object of the present invention is to provide a health functional food composition for inhibiting macrophage killing by triglycerides, comprising an extract of wild grass or a fraction thereof as an active ingredient.
본 발명의 하나의 양태는 산초 추출물 또는 이의 분획물을 유효성분으로 포함하는, 중성지방에 의한 대식세포 사멸 억제용 조성물을 제공한다.
One aspect of the present invention provides a composition for inhibiting macrophage killing by triglycerides, comprising an extract of wild grass or a fraction thereof as an active ingredient.
본 발명에서는, 산초 추출물은 중성지방에 의한 대식세포의 사멸을 억제하는 효과를 나타냄을 확인함에 따라, 상기 산초 추출물 또는 이의 분획물은 중성지방에 의한 대식세포 사멸 억제에 유용하게 사용될 수 있음을 확인하였다.
In the present invention, according to confirming that the pepper extract is effective in inhibiting the death of macrophages by triglycerides, it was confirmed that the pepper extract or its fraction can be usefully used for inhibiting macrophage killing by triglycerides. .
본 발명의 용어, "산초"는 Zanthoxylum schinifolium의 학명을 갖는 식물을 의미한다. 소화불량, 구토, 치통, 이질, 설사 등에 효과를 나타낸다는 것이 공지되었으나, 중성지방에 의한 대식세포 사멸 억제와 관련한 효과는 알려진바 없으며, 본 발명자들에 의해 최초로 규명되었다.The term "sancho" of the present invention is Zanthoxylum It means a plant with the scientific name of schinifolium . Although it is known to have effects on indigestion, vomiting, toothache, dysentery, diarrhea, etc., the effect of inhibiting macrophage death by triglycerides is unknown, and was first identified by the present inventors.
본 발명에서, 상기 산초는 산초의 종자일 수 있으나, 이에 제한되지 않는다. 상기 종자는 과피, 과실 등을 포함하는 열매와는 구분된다.In the present invention, the sancho may be a seed of sancho, but is not limited thereto. The seed is distinguished from the fruit including the peel, fruit, and the like.
상기 산초는 상업적으로 판매되는 것을 구입하거나, 자연에서 채취 또는 재배된 것을 사용할 수 있다.
The sancho can be purchased commercially, or can be used that is harvested or cultivated in nature.
본 발명의 용어, "추출물"은 상기 산초를 추출 처리하여 얻어지는 추출액, 상기 추출액의 희석액이나 농축액, 상기 추출액을 건조하여 얻어지는 건조물, 상기 추출액의 조정제물이나 정제물, 또는 이들의 혼합물 등, 추출액 자체 및 추출액을 이용하여 형성 가능한 모든 제형의 추출물을 포함한다.The term "extract" of the present invention refers to an extract liquid obtained by extracting the above-mentioned wild grass, a diluent or concentrate of the extract, a dried product obtained by drying the extract, a crude product or a purified product of the extract, or a mixture thereof. And extracts of all formulations that can be formed using the extract.
상기 산초를 추출하는 방법은 특별히 제한되지 않으며, 당해 기술 분야에서 통상적으로 사용하는 방법에 따라 추출할 수 있다. 상기 추출 방법의 비제한적인 예로는, 열수 추출법, 초음파 추출법, 여과법, 환류 추출법, 압착 추출법 등을 들 수 있으며, 이들은 단독으로 수행되거나 2종 이상의 방법을 병용하여 수행될 수 있다.The method for extracting the sancho is not particularly limited, and may be extracted according to a method commonly used in the art. Non-limiting examples of the extraction method may include a hot water extraction method, an ultrasonic extraction method, a filtration method, a reflux extraction method, a compression extraction method, and the like, which may be performed alone or in combination of two or more methods.
본 발명에서, 상기 산초 추출물은 산초를 압착하여 제조된 것일 수 있다.
In the present invention, the sancho extract may be prepared by compressing sancho.
본 발명의 용어, "분획물"은 여러 다양한 구성 성분들을 포함하는 혼합물로부터 특정 성분 또는 특정 성분 그룹을 분리하기 위하여 분획을 수행하여 얻어진 결과물을 의미한다.The term "fraction" of the present invention means a result obtained by performing a fraction to separate a specific component or a specific component group from a mixture containing various various constituents.
본 발명에서, 상기 산초 추출물의 분획물을 얻는 분획 방법은 특별히 제한되지 않으며, 당해 기술 분야에서 통상적으로 사용하는 방법에 따라 수행될 수 있다. 상기 분획 방법의 비제한적인 예로는, 다양한 용매를 처리하여 수행하는 용매 분획법, 일정한 분자량 컷-오프 값을 갖는 한외 여과막을 통과시켜 수행하는 한외여과 분획법, 다양한 크로마토그래피(크기, 전하, 소수성 또는 친화성에 따른 분리를 위해 제작된 것)를 수행하는 크로마토그래피 분획법, 및 이들의 조합 등이 있다. 구체적으로, 본 발명의 산초를 추출하여 얻은 추출물에 소정의 용매를 처리하여 상기 추출물로부터 분획물을 얻는 방법을 들 수 있다.In the present invention, the fractionation method for obtaining a fraction of the above-mentioned Sancho extract is not particularly limited, and may be performed according to a method commonly used in the art. Non-limiting examples of the fractionation method include a solvent fractionation method performed by treating various solvents, an ultrafiltration fractionation method performed by passing through an ultrafiltration membrane having a constant molecular weight cut-off value, and various chromatography (size, charge, hydrophobicity) Or a chromatographic fractionation method for performing separation according to affinity), and combinations thereof. Specifically, a method of obtaining a fraction from the extract by treating a predetermined solvent to the extract obtained by extracting the herb of the present invention.
또한, 상기 추출물 또는 분획물은 추출 후 건조 분말 형태로 제조되어 사용될 수 있지만, 이제 제한되는 것은 아니다.
In addition, the extract or fraction may be prepared and used in a dry powder form after extraction, but is not limited.
본 발명에서, 상기 산초 추출물은 중성지방에 의한 대식세포의 사멸을 억제하는 것일 수 있다.In the present invention, the Sancho extract may be to inhibit the death of macrophages by triglycerides.
본 발명의 용어, "중성지방에 의한 대식세포 사멸"은 중성지방(triglyceride)에 의해 대식세포의 기능이 손실 또는 손상되는 것을 의미하며, 대식세포가 괴사(necrosis), 자연사(apoptosis)되거나, 대식세포가 다른 종류의 다른 세포로 전환되는 것을 모두 포함한다. 대식세포는 중성지방이나 사멸된 세포 등 인체에 불필요한 다양한 물질들을 제거하는데, 대식세포의 기능이 손실되는 경우 상술한 물질들에 의해 염증반응이 야기되어, 동맥경화증 등의 질환이 발병할 수 있다. 따라서, 중성지방에 의한 대식세포 사멸은 동맥경화증 등 중성지방에 의한 대식세포 사멸에 의해 발병하는 질환의 예방 또는 치료 용도로서도 유용하게 사용될 수 있다.
The term "macrophage death by triglyceride" in the present invention means that the function of macrophages is lost or impaired by triglyceride, and macrophages are necrosis, apoptosis, or large This includes the conversion of phagocytes to other cells of different types. Macrophages remove various substances unnecessary to the human body, such as triglycerides or dead cells. When the function of macrophages is lost, an inflammatory reaction is caused by the above-described substances, and diseases such as atherosclerosis may occur. Therefore, the death of macrophages by triglycerides can be useful as a preventive or therapeutic use for diseases caused by the death of macrophages by triglycerides such as atherosclerosis.
본 발명의 구체적인 일 실시예에서는, 산초 추출물은 중성지방에 의한 대식세포의 사멸을 억제하여 대식세포의 생존률을 증가시킬 수 있음을 확인하였다(도 1).In a specific embodiment of the present invention, it was confirmed that the Sancho extract can increase the survival rate of macrophages by inhibiting the death of macrophages by triglycerides (FIG. 1).
이는, 상기 산초 추출물은 혈중 지방 농도가 높은 상태에서도 대식세포가 제기능을 유지할 수 있게 하므로, 상기 추출물을 포함하는 본 발명의 조성물은 중성지방에 의한 대식세포 사멸 억제 용도로 유용하게 사용될 수 있음을 시사하는 것이다.
This, because the pepper extract is a high level of fat in the blood to maintain the function of macrophages, the composition of the present invention comprising the extract can be usefully used for inhibiting macrophage death by triglycerides It is suggestive.
본 발명의 조성물은 조성물 총 중량에 대하여 상기 산초 추출물 또는 이의 분획물을 0.001 내지 80, 구체적으로 0.001 내지 70, 더욱 구체적으로 0.001 내지 60 중량%로 포함할 수 있으나, 이에 제한되지 않는다.
The composition of the present invention may include the extract of the herb or a fraction thereof in an amount of 0.001 to 80, specifically 0.001 to 70, and more specifically 0.001 to 60% by weight based on the total weight of the composition, but is not limited thereto.
다른 하나의 양태는 상기 조성물을 개체에 투여하는 단계를 포함하는, 중성지방에 의한 대식세포 사멸 억제 방법을 제공한다.Another aspect provides a method of inhibiting macrophage death by triglycerides, comprising administering the composition to a subject.
이때, 상기 "중성지방에 의한 대식세포 사멸"의 정의는 전술한 바와 같다.
At this time, the definition of the "macrophage death by triglycerides" is as described above.
본 발명의 용어, "투여"는 적절한 방법으로 개체에게 상기 조성물을 도입하는 것을 의미한다.The term "administration" of the present invention means introducing the composition to the individual in an appropriate manner.
본 발명의 용어, "개체"는 중성지방에 의한 대식세포 사멸이 야기되었거나 야기될 수 있는 인간을 포함한 쥐, 생쥐, 가축 등의 모든 동물을 의미한다. 상기 동물은 인간뿐만 아니라 이와 유사한 증상을 갖는 소, 말, 양, 돼지, 염소, 낙타, 영양, 개, 고양이 등의 포유동물일 수 있으나, 이에 제한되지 않는다.
The term "individual" of the present invention means all animals, such as mice, mice, livestock, including humans, which may or may have caused macrophage death by triglycerides. The animals may be mammals such as cows, horses, sheep, pigs, goats, camels, antelopes, dogs, cats, etc., which have similar symptoms as humans, but are not limited thereto.
상기 조성물은 목적하는 방법에 따라 경구 투여하거나 비경구 투여(예를 들어, 정맥 내, 피하, 복강 내 또는 국소에 적용)할 수 있다. 이때, 투여량은 개체의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 시간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 구체적인 예로, 상기 조성물은 일반적으로 0.001 내지 1000 mg/kg, 더욱 구체적으로 0.05 내지 200 mg/kg, 가장 구체적으로 0.1 내지 100 mg/kg의 양을 1일 1회 내지 수회로 나누어 투여할 수 있으나, 바람직한 투여량은 개체의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 당업자에 의해 적절하게 선택될 수 있다.
The composition may be administered orally or parenterally (eg, intravenously, subcutaneously, intraperitoneally, or topically) depending on the desired method. At this time, the dosage varies depending on the condition and weight of the individual, the degree of the disease, the drug form, the administration route and time, but can be appropriately selected by those skilled in the art. As a specific example, the composition may be administered by dividing the amount of 0.001 to 1000 mg / kg, more specifically 0.05 to 200 mg / kg, and most specifically 0.1 to 100 mg / kg, once or several times a day, The preferred dosage may be appropriately selected by a person skilled in the art depending on the condition and weight of the individual, the degree of disease, the drug form, the route and duration of administration.
또 다른 하나의 양태는 산초 추출물 또는 이의 분획물을 유효성분으로 포함하는, 중성지방에 의한 대식세포 사멸 억제용 건강기능식품 조성물을 제공한다.Another aspect provides a health functional food composition for inhibiting macrophage killing by triglycerides, comprising an extract of wild grass or a fraction thereof as an active ingredient.
이때, 상기 "산초", "추출물", "분획물", 및 "중성지방에 의한 대식세포 사멸"의 정의는 전술한 바와 같다.
At this time, the definitions of "wild grass", "extract", "fraction", and "macrophage death by triglycerides" are as described above.
본 발명의 건강기능식품 조성물은 일상적으로 섭취하는 것이 가능하며, 일반 약품과는 달리 천연물을 원료로 하여 약품의 장기 복용 시 발생할 수 있는 부작용 등이 없는 장점이 있으므로, 중성지방에 의한 대식세포 사멸 억제 목적으로 매우 유용하게 사용될 수 있다.
The health functional food composition of the present invention can be consumed on a daily basis, and unlike other medicines, it has the advantage that there is no side effect that can occur when taking medicines for a long time by using natural substances as raw materials, and thus inhibits macrophage death by triglycerides. It can be very useful for purposes.
본 발명의 용어, "건강기능식품"(health functional food)은 특정보건용 식품(food for special health use, FoSHU)과 동일한 용어로, 영양 공급 외에도 생체조절기능이 효율적으로 나타나도록 가공된 의학, 의료효과가 높은 식품을 의미한다. 여기서 '기능'은 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건용도에 유용한 효과를 얻는 것을 의미한다. 경우에 따라, 건강기능식품, 건강식품, 건강보조식품의 용어는 호용될 수 있다.The term “health functional food” in the present invention is the same term as food for special health use (FoSHU), and medicine and medical treatment processed to efficiently exhibit bioregulatory functions in addition to nutrition. It means food with high effectiveness. Here, the term 'function' means to obtain a useful effect for health use such as adjusting nutrients or physiological effects on the structure and function of the human body. In some cases, the terms health functional food, health food, and health supplement may be used interchangeably.
구체적으로, 상기 건강기능식품은 본 발명의 산초 추출물 또는 이의 분획물을 음료, 차류, 향신료, 껌, 과자류 등의 식품 소재에 첨가하거나, 캡슐화, 분말화, 현탁액 등으로 제조한 식품으로, 이를 섭취할 경우 건강상 특정한 효과를 가져오는 것을 의미하나, 일반 약품과는 달리 식품을 원료로 하여 약품의 장기 복용 시 발생할 수 있는 부작용이 없는 장점이 있다.
Specifically, the health functional food is a food prepared by adding the herbal extract or fractions thereof of the present invention to food materials such as beverages, teas, spices, gums, confectionery, or by encapsulation, powdering, suspension, etc. In this case, it means that it has a certain effect on health, but unlike general medicines, it has the advantage that there is no side effect that can occur when taking medicines for a long time using food as a raw material.
본 발명의 건강기능식품은 당업계에서 통상적으로 사용되는 방법에 의하여 제조 가능하며, 당업계에서 통상적으로 첨가하는 원료 및 성분을 첨가하여 제조할 수 있다. 또한, 상기 건강기능식품 조성물은 식품으로 인정되는 제형이면 다양한 형태의 제형으로 제한 없이 제조될 수 있다.The health functional food of the present invention can be prepared by a method conventionally used in the art, and can be prepared by adding raw materials and ingredients commonly added in the art. In addition, the health functional food composition may be prepared without limitation as various types of formulations as long as the formulation is recognized as food.
또한, 상기 건강기능식품 조성물은 생리학적으로 허용 가능한 담체를 추가로 포함할 수 있는데, 담체의 종류는 특별히 제한되지 않으며 당해 기술 분야에서 통상적으로 사용되는 담체라면 어느 것이든 사용할 수 있다.In addition, the health functional food composition may further include a physiologically acceptable carrier, and the type of the carrier is not particularly limited, and any carrier commonly used in the art may be used.
또한, 상기 건강기능식품 조성물은 식품 조성물에 통상 사용되어 냄새, 맛, 시각 등을 향상시킬 수 있는 추가 성분을 포함할 수 있다. 예들 들어, 비타민 A, C, D, E, B1, B2, B6, B12, 니아신(niacin), 비오틴(biotin), 폴레이트(folate), 판토텐산(panthotenic acid) 등을 포함할 수 있다. 또한, 아연(Zn), 철(Fe), 칼슘(Ca), 크롬(Cr), 마그네슘(Mg), 망간(Mn), 구리(Cu), 크륨(Cr) 등의 미네랄; 및 라이신, 트립토판, 시스테인, 발린 등의 아미노산을 포함할 수 있다.In addition, the health functional food composition is commonly used in food composition may include an additional component that can improve the smell, taste, vision, and the like. For example, vitamin A, C, D, E, B1, B2, B6, B12, niacin, biotin, folate, pantotenic acid, and the like. In addition, minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn), copper (Cu), and chromium (Cr); And amino acids such as lysine, tryptophan, cysteine, and valine.
또한, 상기 건강기능식품 조성물은 방부제(소르빈산 칼륨, 벤조산나트륨, 살리실산, 데히드로초산나트륨 등), 살균제(표백분과 고도 표백분, 차아염소산나트륨 등), 산화방지제(부틸히드록시아니졸(BHA), 부틸히드록시톨류엔(BHT) 등), 착색제(타르색소 등), 발색제(아질산 나트륨, 아초산 나트륨 등), 표백제(아황산나트륨), 조미료(MSG 글루타민산나트륨 등), 감미료(둘신, 사이클레메이트, 사카린, 나트륨 등), 향료(바닐린, 락톤류 등), 팽창제(명반, D-주석산수소칼륨 등), 강화제, 유화제, 증점제(호료), 피막제, 검기초제, 거품억제제, 용제, 개량제 등의 식품 첨가물(food additives)을 포함할 수 있다. 상기 첨가물은 식품의 종류에 따라 선별하고 적절한 양으로 사용할 수 있다.
In addition, the health functional food composition is a preservative (potassium sorbate, sodium benzoate, salicylic acid, sodium dehydroacetate, etc.), fungicides (bleached and highly bleached, sodium hypochlorite, etc.), antioxidants (butyl hydroxyanisole (BHA), Butyl hydroxytoluene (BHT, etc.), colorants (such as tar color), colorants (sodium nitrite, sodium nitrite, etc.), bleach (sodium sulfite), seasonings (such as MSG sodium glutamate), sweeteners (dulcin, cyclate) , Saccharin, sodium, etc.), fragrances (vanillin, lactones, etc.), swelling agents (alum, D-potassium hydrogen sulphate, etc.), strengthening agents, emulsifiers, thickeners (foaming agents), coating agents, gum starting agents, foam inhibitors, solvents, improvers, etc. May include food additives. The additive may be selected according to the type of food and used in an appropriate amount.
본 발명의 산초 추출물을 포함하는 조성물은 혈중 지방 농도가 높은 상태에서도 대식세포의 기능을 유지할 수 있게 하므로, 중성지방에 의한 대식세포 사멸 억제 용도로서 유용하게 사용될 수 있다.
Since the composition comprising the extract of the herb of the present invention can maintain the function of macrophages even in a state where the concentration of fat in the blood is high, it can be usefully used for the purpose of inhibiting macrophage death by triglycerides.
도 1은 본 발명의 일 실시예에 따라 제조한, 산초 추출물의 중성지방에 의한 대식세포의 사멸 억제 효과를 보여주는 그래프이다. 세포 생존율(cell viability)은 정상 대조군(control)에 대한 것으로 나타내었다. 이때, TG는 중성지방(triglyceride)을 의미한다. 1 is a graph prepared according to an embodiment of the present invention, showing the effect of inhibiting the killing of macrophages by triglycerides of the pepper extract. Cell viability was shown to be relative to a normal control. At this time, TG means triglyceride.
이하, 하기 실시예 및 실험예에 의하여 본 발명을 보다 상세히 설명하고자 한다. 그러나, 하기 실시예 및 실험예는 본 발명을 예시하기 위한 것으로 본 발명의 범위가 이들만으로 한정되는 것은 아니다.
Hereinafter, the present invention will be described in more detail by the following examples and experimental examples. However, the following examples and experimental examples are intended to illustrate the present invention, and the scope of the present invention is not limited thereto.
제조예Manufacturing example 1. 산초 추출물 제조 1. Preparation of Sancho Extract
음건한 산초 종자를 조분쇄한 후, 92 내지 98℃로 예열된 찜통에 넣어 5분간 증숙하였다. 이후, 착유기에서 600kg/cm2의 압력으로 15분간 압착하여 산초 추출물을 제조하였다.
After coarsely pulverizing the shaded sancho seeds, they were put in a steamer preheated to 92 to 98 ° C and steamed for 5 minutes. Subsequently, the extract was prepared by squeezing for 15 minutes at a pressure of 600 kg / cm 2 in a milking machine.
실시예Example 1. 산초 추출물의 항동맥경화 효과 확인 1. Confirmation of anti-atherosclerotic effect of Sancho extract
상기 제조예 1에 따라 제조한 산초 추출물의 항동맥경화 효과를 확인하기 위하여, 중성지방에 의한 대식세포의 사멸 억제 효과를 확인하였다.In order to confirm the anti-atherosclerotic effect of the Sancho extract prepared according to Preparation Example 1, the effect of inhibiting the death of macrophages by triglycerides was confirmed.
구체적으로, 인간의 단핵 세포주 THP-1을 96웰 플레이트에 1.5×104 세포/웰의 수로 접종한 후, 200nM PMA(phorbol-12-myristate-13-acetate)를 24시간 동안 처리하여 대식세포로 분화를 유도하였다. 분화한 대식세포를 37℃, 5% 이산화탄소 조건에서 1% 페니실린-스트렙토마이신, 10% 우태아혈청을 포함한 RPMI 배지를 이용하여 유지하였고, 0.2 내지 2 ㎕/㎖ 농도의 산초 추출물을 24시간 동안 처리하였다. 이후, DPBS로 상기 세포를 2회 세척하고, 1 ㎎/㎖ 농도의 중성지방(triglyceride; TG)을 24시간 동안 처리하였다. 상기의 과정이 끝난 대식세포에 대하여 Ez-Cytox(도진바이오)를 사용하여 세포 생존률을 측정하였다.Specifically, the human mononuclear cell line THP-1 was inoculated into a 96-well plate at a number of 1.5 × 10 4 cells / well, and then treated with 200 nM PMA (phorbol-12-myristate-13-acetate) for 24 hours to macrophages. Differentiation was induced. Differentiated macrophages were maintained using RPMI medium containing 1% penicillin-streptomycin, 10% fetal bovine serum at 37 ° C and 5% carbon dioxide conditions, and treated with 0.2-2 µl / mL concentration of pepper extract for 24 hours. Did. Then, the cells were washed twice with DPBS, and triglyceride (TG) at a concentration of 1 mg / ml was treated for 24 hours. Cell viability was measured using Ez-Cytox (Dojin Bio) for macrophages after the above process.
그 결과, 도 1에서 볼 수 있듯이, 산초 추출물을 처리하는 경우, 중성지방에 의해 감소한 대식세포의 생존률이 증가하는 것을 확인하였고, 이러한 증가 효과는 정상 대조군과도 유사한 정도임을 확인하였다.As a result, as can be seen in Figure 1, when processing the extract, it was confirmed that the survival rate of macrophages reduced by triglycerides increased, it was confirmed that this increase effect is similar to the normal control.
상기 결과를 통해, 산초 추출물은 중성지방에 의한 대식세포의 사멸을 효과적으로 억제하므로, 대식세포 사멸에 따른 면역기능 저하, 중성지방 대사기능 저하, 거품세포 형성, 형성된 거품세포의 제거기능 저하 등을 억제하여 동맥경화의 예방 또는 치료에 유용하게 사용될 수 있음을 알 수 있었다.
Through the above results, the Sancho extract effectively suppresses the death of macrophages caused by triglycerides, thereby suppressing the immune function decrease due to the death of macrophages, the deterioration of triglyceride metabolism, the formation of foam cells, and the reduction of the removal function of the formed foam cells. Therefore, it was found that it can be usefully used for the prevention or treatment of arteriosclerosis.
이상의 설명으로부터, 본 발명이 속하는 기술분야의 당업자는 본 발명이 그 기술적 사상이나 필수적 특징을 변경하지 않고서 다른 구체적인 형태로 실시될 수 있다는 것을 이해할 수 있을 것이다. 이와 관련하여, 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며 한정적인 것이 아닌 것으로 이해해야만 한다. 본 발명의 범위는 상기 상세한 설명보다는 후술하는 특허 청구범위의 의미 및 범위 그리고 그 등가 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.From the above description, those skilled in the art to which the present invention pertains will understand that the present invention may be implemented in other specific forms without changing its technical spirit or essential characteristics. In this regard, it should be understood that the embodiments described above are illustrative in all respects and not restrictive. The scope of the present invention should be construed as including all changes or modifications derived from the meaning and scope of the following claims rather than the above detailed description and equivalent concepts thereof.
Claims (5)
A composition for inhibiting macrophage killing due to triglycerides, comprising an extract of Sancho or its fraction as an active ingredient.
The composition according to claim 1, wherein the wild grass is a seed of wild grass.
The composition of claim 1, wherein the extract is prepared by squeezing wild pepper.
A method of inhibiting macrophage death by triglycerides, comprising administering the composition of any one of claims 1 to 3 to an individual other than a human.
A health functional food composition for inhibiting macrophage killing by triglycerides, comprising an extract of wild grass or a fraction thereof as an active ingredient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180122744A KR102143968B1 (en) | 2018-10-15 | 2018-10-15 | Compositions for for inhibiting of macrophage death by triglycerides comprising extracts of Angelica takeshimana |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180122744A KR102143968B1 (en) | 2018-10-15 | 2018-10-15 | Compositions for for inhibiting of macrophage death by triglycerides comprising extracts of Angelica takeshimana |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20200042311A true KR20200042311A (en) | 2020-04-23 |
KR102143968B1 KR102143968B1 (en) | 2020-08-12 |
Family
ID=70472614
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020180122744A KR102143968B1 (en) | 2018-10-15 | 2018-10-15 | Compositions for for inhibiting of macrophage death by triglycerides comprising extracts of Angelica takeshimana |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102143968B1 (en) |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20080041441A (en) * | 2006-11-07 | 2008-05-13 | 한국생명공학연구원 | Composition containing extracts of zanthoxylum piperitum dc or compounds isolated therefrom for the prevention and treatment of cardiovascular diseases |
KR20100042819A (en) * | 2008-10-17 | 2010-04-27 | 한국국제대학교 산학협력단 | Cosmetic composition comprising oil of zanthoxylum schinifolium for treatment of atopic dermatitis |
KR20100122333A (en) * | 2009-05-12 | 2010-11-22 | 한국생명공학연구원 | Compositions for the prevention and treatment of obesity, hyperlipidemia, atherosclerosis, fatty liver, diabetes mellitus or metabolic syndrome comprising extracts or fractions of glycine max leaves as an active ingredient |
KR20110067216A (en) * | 2009-12-14 | 2011-06-22 | 주식회사 코리아나화장품 | Cosmetic compositions comprising mixed extracts of zanthoxylum schinifolium, pulsatilla koreana, usnea barbata, illicium verum hooker fil., echinacea and propolis |
KR20120021994A (en) * | 2010-08-25 | 2012-03-09 | 이명섭 | Composition comprising the extract of chinese pepper for immune activity |
WO2014021637A1 (en) * | 2012-07-31 | 2014-02-06 | 가톨릭대학교 산학협력단 | Composition comprising rebamipide as active ingredient for preventing or treating hyperlipemia and diseases associated therewith |
KR20150061043A (en) * | 2013-10-30 | 2015-06-04 | 동의대학교 산학협력단 | Composition for immunosuppressing comprising alcohol extract of chinese pepper or fraction thereof |
KR20160033063A (en) * | 2015-10-08 | 2016-03-25 | 고려대학교 산학협력단 | Pharmaceutical composition for prevention or treatment of blood vessel disease containing extracts of Morus alba stem having activity preventing from the atherogenic legion formation and foam cell formation |
KR101611852B1 (en) * | 2015-02-24 | 2016-04-12 | 주식회사 한빛향료 | Food composition with Sancho seed oil for prevention or improvement of arteriosclerosis |
KR20160058989A (en) * | 2014-11-06 | 2016-05-26 | 동의대학교 산학협력단 | Composition of anti-obesity containing extract of zanthoxylum schinifolium and method of making the same |
KR101672708B1 (en) * | 2015-09-14 | 2016-11-04 | 한림대학교 산학협력단 | - Food composition for improvement of atherosclerosis and pharmaceutical compositions for treatment of atherosclerosis with extract of Perilla frutescens or -asarone from Perilla frutescens |
-
2018
- 2018-10-15 KR KR1020180122744A patent/KR102143968B1/en active IP Right Grant
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20080041441A (en) * | 2006-11-07 | 2008-05-13 | 한국생명공학연구원 | Composition containing extracts of zanthoxylum piperitum dc or compounds isolated therefrom for the prevention and treatment of cardiovascular diseases |
KR20100042819A (en) * | 2008-10-17 | 2010-04-27 | 한국국제대학교 산학협력단 | Cosmetic composition comprising oil of zanthoxylum schinifolium for treatment of atopic dermatitis |
KR20100122333A (en) * | 2009-05-12 | 2010-11-22 | 한국생명공학연구원 | Compositions for the prevention and treatment of obesity, hyperlipidemia, atherosclerosis, fatty liver, diabetes mellitus or metabolic syndrome comprising extracts or fractions of glycine max leaves as an active ingredient |
KR20110067216A (en) * | 2009-12-14 | 2011-06-22 | 주식회사 코리아나화장품 | Cosmetic compositions comprising mixed extracts of zanthoxylum schinifolium, pulsatilla koreana, usnea barbata, illicium verum hooker fil., echinacea and propolis |
KR20120021994A (en) * | 2010-08-25 | 2012-03-09 | 이명섭 | Composition comprising the extract of chinese pepper for immune activity |
WO2014021637A1 (en) * | 2012-07-31 | 2014-02-06 | 가톨릭대학교 산학협력단 | Composition comprising rebamipide as active ingredient for preventing or treating hyperlipemia and diseases associated therewith |
KR20150061043A (en) * | 2013-10-30 | 2015-06-04 | 동의대학교 산학협력단 | Composition for immunosuppressing comprising alcohol extract of chinese pepper or fraction thereof |
KR20160058989A (en) * | 2014-11-06 | 2016-05-26 | 동의대학교 산학협력단 | Composition of anti-obesity containing extract of zanthoxylum schinifolium and method of making the same |
KR101611852B1 (en) * | 2015-02-24 | 2016-04-12 | 주식회사 한빛향료 | Food composition with Sancho seed oil for prevention or improvement of arteriosclerosis |
KR101672708B1 (en) * | 2015-09-14 | 2016-11-04 | 한림대학교 산학협력단 | - Food composition for improvement of atherosclerosis and pharmaceutical compositions for treatment of atherosclerosis with extract of Perilla frutescens or -asarone from Perilla frutescens |
KR20160033063A (en) * | 2015-10-08 | 2016-03-25 | 고려대학교 산학협력단 | Pharmaceutical composition for prevention or treatment of blood vessel disease containing extracts of Morus alba stem having activity preventing from the atherogenic legion formation and foam cell formation |
Also Published As
Publication number | Publication date |
---|---|
KR102143968B1 (en) | 2020-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20120002131A (en) | Composition for treating or preventing obesity containing curcuma longa extract | |
KR101621447B1 (en) | Pharmaceutical composition for anti-obesity comprising complex extracts including Saururi chinensis Baill. extract, Curcumae Longae Rhizoma extract and Polygalae Radix extract | |
KR102150122B1 (en) | Antioxidant composition comprising extract of Apis mellifera male pupa | |
KR101749967B1 (en) | A pharmaceutical composition comprising extract from germinated gemmule of bean for preventing or treating obesity | |
KR102081984B1 (en) | A pharmaceutical composition comprising extract from wheat sprowt for preventing or treating osteoporosis | |
KR101807080B1 (en) | Antioxidant or antiinflammatory composition comprising clamworm | |
KR102143968B1 (en) | Compositions for for inhibiting of macrophage death by triglycerides comprising extracts of Angelica takeshimana | |
KR102235563B1 (en) | Composition for fatigue recovery and sexual function improvement containing high content of arginine | |
KR20140036966A (en) | Composition for improving exercise capacity or a composition for reducing fatigue using leaves of sasa quelpaertensis | |
KR101636608B1 (en) | Composition for antioxidation comprising the seed extract of cornus officinalis | |
KR102184812B1 (en) | A composition for prevention and treatment of osteoporosis comprising extracts of Saechalssalbori | |
KR101939906B1 (en) | Composition for prevention or treatment of brain diseases comprising of Lysimachia christinae Hance extract or fraction thereof | |
KR101886299B1 (en) | Compositions for Preventing, Improving or Treating Obesity and Metabolic Diseases Comprising Combined Extracts of Peach Blossom and Lotus Leaf | |
KR101257329B1 (en) | Composition for treating or preventing obesity containing stichpus japonicus extract | |
KR20180006612A (en) | Compositions for preventing or treating diabetes mellitus comprising extract of Aster koraiensis or fraction thereof | |
KR20150085215A (en) | Composition comprising black garlic and Gastrodia elata extract with antioxidant activity and method of making the same | |
KR102594107B1 (en) | Composition for antifatique or exercise performance comprising mixed extract of Atractylodes macrocephala and Agastache rugosa | |
KR20190135177A (en) | Composition for preventing and/or treating a degenerative brain disease comprising as an active ingredient an extract of Cimicifuga dahurica, a fraction thereof, or a compound derived from Cimicifuga dahurica | |
KR20180130868A (en) | Composition for prevention or treatment of cognitive dysfunction based on brain nerve cell protection comprising of Gynura procumbens extract or fraction thereof | |
KR102282883B1 (en) | Composition for preventing and/or treating a degenerative brain disease comprising as an active ingredient an extract of Cimicifuga dahurica, a fraction thereof, or a compound derived from Cimicifuga dahurica | |
KR20130102305A (en) | Composition for liver protection and improving liver function and functional food comprising thererof | |
KR101886314B1 (en) | Compositions for Preventing, Improving or Treating Obesity and Metabolic Diseases Comprising Combined Extracts of Peach Blossom and Water Chestnut | |
KR102281263B1 (en) | Enzyme treated catechin product containing increased gallic acid, epicatechin and epigallocatechin content and preparation method thereof | |
EP3023103A1 (en) | Pharmaceutical composition for anti-obesity comprising complex extracts including Saururi chinensis Baill. extract, Curcumae longae rhizoma extract and Polygalae radix extract | |
KR20110078237A (en) | Composition for treating or preventing obesity containing eriobotrya japonica extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AMND | Amendment | ||
E601 | Decision to refuse application | ||
X091 | Application refused [patent] | ||
AMND | Amendment | ||
X701 | Decision to grant (after re-examination) | ||
GRNT | Written decision to grant |